AU2007275764B2 - Methods for treating pain and screening analgesic compounds - Google Patents

Methods for treating pain and screening analgesic compounds Download PDF

Info

Publication number
AU2007275764B2
AU2007275764B2 AU2007275764A AU2007275764A AU2007275764B2 AU 2007275764 B2 AU2007275764 B2 AU 2007275764B2 AU 2007275764 A AU2007275764 A AU 2007275764A AU 2007275764 A AU2007275764 A AU 2007275764A AU 2007275764 B2 AU2007275764 B2 AU 2007275764B2
Authority
AU
Australia
Prior art keywords
tyr
rgia
iodo
fluorescent tag
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007275764A
Other languages
English (en)
Other versions
AU2007275764A1 (en
Inventor
Michael A. Ellison
J. Michael Mcintosh
Baldomero M. Olivera
Michelle Vincler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2007275764A1 publication Critical patent/AU2007275764A1/en
Application granted granted Critical
Publication of AU2007275764B2 publication Critical patent/AU2007275764B2/en
Priority to AU2014200739A priority Critical patent/AU2014200739A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
AU2007275764A 2006-07-18 2007-07-17 Methods for treating pain and screening analgesic compounds Ceased AU2007275764B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014200739A AU2014200739A1 (en) 2006-07-18 2014-02-12 Methods for treating pain and screening analgesic compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83146806P 2006-07-18 2006-07-18
US60/831,468 2006-07-18
PCT/US2007/016163 WO2008011006A2 (en) 2006-07-18 2007-07-17 Methods for treating pain and screening analgesic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014200739A Division AU2014200739A1 (en) 2006-07-18 2014-02-12 Methods for treating pain and screening analgesic compounds

Publications (2)

Publication Number Publication Date
AU2007275764A1 AU2007275764A1 (en) 2008-01-24
AU2007275764B2 true AU2007275764B2 (en) 2013-11-14

Family

ID=38957314

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007275764A Ceased AU2007275764B2 (en) 2006-07-18 2007-07-17 Methods for treating pain and screening analgesic compounds

Country Status (6)

Country Link
US (1) US9717775B2 (enExample)
EP (1) EP2051726B1 (enExample)
JP (2) JP5558817B2 (enExample)
AU (1) AU2007275764B2 (enExample)
CA (1) CA2657532C (enExample)
WO (1) WO2008011006A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
JP5558817B2 (ja) * 2006-07-18 2014-07-23 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 痛みの処置方法および鎮痛化合物のスクリーニング方法
JP6681826B2 (ja) * 2013-05-31 2020-04-15 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション コノトキシンペプチド、医薬組成物およびそれらの使用
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
EP4393502A2 (en) * 2018-12-26 2024-07-03 Skinmed Co., Ltd. Acetylcholine receptor inhibitory peptides and uses thereof
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
SG11202106847SA (en) * 2019-01-04 2021-07-29 Kineta Chronic Pain Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
US12227771B2 (en) 2019-05-17 2025-02-18 Janssen Pharmaceutica Nv Expression systems and methods of use thereof
CN113493502B (zh) * 2020-04-01 2023-09-12 广西大学 α-芋螺毒素肽TxIE、其药物组合物及用途
EP4378950A4 (en) * 2021-07-27 2025-10-15 Skinmed Co Ltd OPTIMIZED SHORTENED PEPTIDE THAT BINDS TO THE ACETYLCHOLINE RECEPTOR, AND ITS USE
CN117794942A (zh) * 2021-07-27 2024-03-29 思亲美有限公司 乙酰胆碱受体结合优化短肽及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215480A1 (en) * 2001-03-29 2005-09-29 Livett Bruce G Alpha conotoxin peptides with analgesic properties
US6958323B2 (en) * 1997-12-31 2005-10-25 University of Utah Research Fnd. Uses of α-conotoxin peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
WO1994025503A1 (en) 1993-04-27 1994-11-10 Cytotherapeutics, Inc. Membrane formed by an acrylonitrile-based polymer
AU688776B2 (en) 1993-06-23 1998-03-19 Brown University Research Foundation Method and apparatus for sealing implantable, membrane encapsulation devices
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
IN181898B (enExample) 1995-06-07 1998-10-24 Cytotherapeutics Inc
WO1997012635A1 (en) 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
WO1997035478A1 (en) * 1996-03-26 1997-10-02 The Regents Of The University Of California Selective target cell activation by expression of a g protein-coupled receptor activated superiorly by synthetic ligand
US5844077A (en) 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
AU3473800A (en) * 1999-01-29 2000-08-18 University Of Utah Research Foundation Conotoxin peptides
JP2002534996A (ja) * 1999-01-29 2002-10-22 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション アルファ−コノトキシン・ペプチド
AU780460B2 (en) * 1999-09-15 2005-03-24 Janssen Pharmaceutica N.V. Nicotinic acetylcholine receptor alpha10 subunit
EP1090991A1 (en) * 1999-09-29 2001-04-11 Sanofi-Synthelabo Novel nicotinic acetylcholine receptor subunit, its isolation and use
US20030109670A1 (en) * 2001-02-09 2003-06-12 University Of Utah Research Foundation Cone snail peptides
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
AU2006236006B2 (en) * 2006-04-13 2012-09-06 The University Of Queensland Cyclised a-conotoxin peptides
JP5558817B2 (ja) * 2006-07-18 2014-07-23 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 痛みの処置方法および鎮痛化合物のスクリーニング方法
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958323B2 (en) * 1997-12-31 2005-10-25 University of Utah Research Fnd. Uses of α-conotoxin peptides
US20050215480A1 (en) * 2001-03-29 2005-09-29 Livett Bruce G Alpha conotoxin peptides with analgesic properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. M. MCINTOSH: "A Novel-Conotoxin, PeIA, Cloned from Conus pergrandis, Discriminates between Rat 9 10 and 7 Nicotinic Cholinergic Receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 34,1 January 2005 (2005-01-01), pages 30107-30112, *
Johnson D.S. et al. Molecular Pharmacology, 1995, vol. 48, pages 194-199 *

Also Published As

Publication number Publication date
JP5953338B2 (ja) 2016-07-20
US9717775B2 (en) 2017-08-01
EP2051726B1 (en) 2018-04-18
JP2009545526A (ja) 2009-12-24
US20090203616A1 (en) 2009-08-13
EP2051726A2 (en) 2009-04-29
JP2014210784A (ja) 2014-11-13
JP5558817B2 (ja) 2014-07-23
CA2657532A1 (en) 2008-01-24
WO2008011006A3 (en) 2008-06-19
WO2008011006A2 (en) 2008-01-24
AU2007275764A1 (en) 2008-01-24
EP2051726A4 (en) 2012-06-20
CA2657532C (en) 2019-06-18

Similar Documents

Publication Publication Date Title
CA2657532C (en) Methods for treating pain and screening analgesic compounds
US9284358B2 (en) Conotoxin peptides
US8716436B2 (en) Mu opioid receptor agonist analogs of the endomorphins
AU2019240693B2 (en) Kv1.3 potassium channel antagonists
Zhang et al. Development of multifunctional and orally active cyclic peptide agonists of opioid/neuropeptide FF receptors that produce potent, long-lasting, and peripherally restricted antinociception with diminished side effects
CN101745097A (zh) 特异阻断乙酰胆碱受体的海南产α-芋螺毒素及其用途
US20170369531A1 (en) Mu opioid receptor agonist analogs of the endomorphins
CN105985410B (zh) 芋螺肽、其药物组合物及用途
US20160122388A1 (en) Conotoxin peptides, pharmaceutical compositions and uses thereof
US20120122803A1 (en) Alpha-conotoxin mii analogs
EP2580233B1 (en) Materials and method for suppressing inflammatory and neuropathic pain
WO1993010145A1 (en) Compositions for delayed treatment of ischemia-related neuronal damage
AU2022246283A1 (en) Use of adnf polypeptides in therapy
US6403325B1 (en) Methods and compounds for treating alzheimer's disease
US20030167129A1 (en) Binding compounds and methods for identifying binding compounds
AU2014200739A1 (en) Methods for treating pain and screening analgesic compounds
Mueller Engineering an optimized analgesic from the NaV1. 7 selective spider venom peptide Pn3a
Erdei Biochemical, functional and pharmacological characterization of novel bifunctional peptide ligands and nociceptin variants
Polt Glycopeptides as Analgesics: Non-Toxic Alternatives to Morphine for Combat Casualty Care
HK1246811B (en) Mu opioid receptor agonist analogs of the endomorphins
HK1235416B (en) Kv1.3 potassium channel antagonists
HK1235416A1 (en) Kv1.3 potassium channel antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired